Interruption of OX40L signaling prevents costimulation blockade–resistant allograft rejection

The potential of costimulation blockade to serve as a novel transplant immunosuppression strategy has been explored for over 20 years, culminating in the recent clinical approval of belatacept for renal transplant patients. Despite improving long-term graft function and survival compared with calcin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Kitchens, William H., Dong, Ying, Mathews, David V., Breeden, Cynthia P., Strobert, Elizabeth, Fuentes, Maria E., Larsen, Christian P., Ford, Mandy L., Adams, Andrew B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2017
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5333968/
https://ncbi.nlm.nih.gov/pubmed/28289708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.90317
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia